Repurposing of Immunomodulators for the Treatment of Cancer with QSAR Approaches

Abstract

Natural products with immunomodulatory activity are widely used to treat many diseases, including autoimmune diseases, inflammatory disorders and other cancer treatments. Over the last decades, the immunomodulators agent increased their interest as the therapeutic agents against various conditions, including cancer diseases. Furthermore, they also provide inexpensive and less toxic extracts from the plants compared to other chemical poisonous chemotherapy and radiotherapy types of treatment. The advances in the computational field technology, methods such as QSAR studies, docking and receptor–drug interaction, provide better-promising drug repurposed options for cancer treatment with lesser side effects. The CADD studies enhance the repurposed drug uses with the detailed insight into biological mechanism understanding through the binding and interaction role with the natural target, which results in improved outcomes therapeutically. We have described the immunomodulatory mechanism associated with the cancer treatment involving the cytokines, adjuvants, checkpoints, and agonists and hypothesized restricting tumour development by interrupting the tumour cell cycle and promoting apoptosis. Among several therapeutic classes, immunomodulators have become a hot new area of research in oncology that is erupting with the activity, which is the main focus of this chapter.